Big pharma investing in regenerative medicine


Large cap pharma and biotech firms have regenerative therapy R&D programs underway according to a recent survey.

69% of respondents are focused on developing cellular-based therapies.

Wound healing and burns have the greatest near-term potential.

Long term areas of interest are cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease.

(AGN) (AMGN) (BAX) (BIIB) (CELG) (LLY) (GSK) (JNJ) (NVS) (NVO) (PFE) (RHHBY) (SNY) (MRK) (SHPG)

From other sites
Comments (2)
  • rongood
    , contributor
    Comments (11) | Send Message
     
    And the news is?
    26 Mar 2014, 09:09 AM Reply Like
  • Joe McCann
    , contributor
    Comments (256) | Send Message
     
    Should probably mention the MDWD IPO in this since they are a burn play.

     

    I bought the IPO, but slightly worried if this is true now that MDWD was willing to price at the low end of their range in a M&A hungry landscape.

     

    Remember Shire bought Advanced BioHealing the night before they IPO'ed, in 2011, so companies are debating M&A vs. IPO right up until the last minute.

     

    Maybe their product isn't regenerative enough, and really more just burn wound medicine?
    26 Mar 2014, 12:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs